Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366352303> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4366352303 endingPage "430" @default.
- W4366352303 startingPage "421" @default.
- W4366352303 abstract "Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1-3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated 5 once daily (QD) surufatinib doses (3 + 3 design) to identify maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and evaluate safety and efficacy at the RP2D in 4 disease-specific expansion cohorts including pancreatic neuroendocrine tumors [pNET] and extrapancreatic NETs [epNET]. MTD and RP2D were 300 mg QD (escalation [n = 35]); 5 patients (15.6%) (Dose Limiting Toxicity [DLT] Evaluable Set [n = 32]) had DLTs. Pharmacokinetics were dose proportional. Estimated progression-free survival (PFS) rates at 11 months were 57.4% (95% confidence interval [CI]: 28.7, 78.2) and 51.1% (95% CI: 12.8, 80.3) for pNET and epNET expansion cohorts, respectively. Median PFS was 15.2 (95% CI: 5.2, not evaluable) and 11.5 (95% CI: 6.5,11.5) months. Response rates were 18.8% and 6.3%. The most frequent treatment-emergent adverse events (both cohorts) were fatigue (46.9%), hypertension (43.8%), proteinuria (37.5%), diarrhea (34.4%). Pharmacokinetics, safety, and antitumor efficacy of 300 mg QD oral surufatinib in US patients with pNETs and epNETs are consistent with previously reported studies in China and may support applicability of earlier surufatinib studies in US patients. Clinical trial registration: Clinicaltrials.gov NCT02549937." @default.
- W4366352303 created "2023-04-21" @default.
- W4366352303 creator A5003060935 @default.
- W4366352303 creator A5004714469 @default.
- W4366352303 creator A5010034986 @default.
- W4366352303 creator A5016574266 @default.
- W4366352303 creator A5017504528 @default.
- W4366352303 creator A5024783288 @default.
- W4366352303 creator A5035136964 @default.
- W4366352303 creator A5037942451 @default.
- W4366352303 creator A5044607993 @default.
- W4366352303 creator A5069777765 @default.
- W4366352303 creator A5090715224 @default.
- W4366352303 date "2023-04-19" @default.
- W4366352303 modified "2023-10-16" @default.
- W4366352303 title "A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors" @default.
- W4366352303 cites W2583252578 @default.
- W4366352303 cites W2608160487 @default.
- W4366352303 cites W2900478373 @default.
- W4366352303 cites W2912003477 @default.
- W4366352303 cites W2915064532 @default.
- W4366352303 cites W2920708123 @default.
- W4366352303 cites W3015314028 @default.
- W4366352303 cites W3087238097 @default.
- W4366352303 cites W3087682866 @default.
- W4366352303 cites W3137935410 @default.
- W4366352303 cites W3181412354 @default.
- W4366352303 cites W3192494717 @default.
- W4366352303 doi "https://doi.org/10.1007/s10637-023-01359-2" @default.
- W4366352303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37074571" @default.
- W4366352303 hasPublicationYear "2023" @default.
- W4366352303 type Work @default.
- W4366352303 citedByCount "0" @default.
- W4366352303 crossrefType "journal-article" @default.
- W4366352303 hasAuthorship W4366352303A5003060935 @default.
- W4366352303 hasAuthorship W4366352303A5004714469 @default.
- W4366352303 hasAuthorship W4366352303A5010034986 @default.
- W4366352303 hasAuthorship W4366352303A5016574266 @default.
- W4366352303 hasAuthorship W4366352303A5017504528 @default.
- W4366352303 hasAuthorship W4366352303A5024783288 @default.
- W4366352303 hasAuthorship W4366352303A5035136964 @default.
- W4366352303 hasAuthorship W4366352303A5037942451 @default.
- W4366352303 hasAuthorship W4366352303A5044607993 @default.
- W4366352303 hasAuthorship W4366352303A5069777765 @default.
- W4366352303 hasAuthorship W4366352303A5090715224 @default.
- W4366352303 hasBestOaLocation W43663523031 @default.
- W4366352303 hasConcept C112705442 @default.
- W4366352303 hasConcept C121608353 @default.
- W4366352303 hasConcept C126322002 @default.
- W4366352303 hasConcept C143998085 @default.
- W4366352303 hasConcept C197934379 @default.
- W4366352303 hasConcept C2778820342 @default.
- W4366352303 hasConcept C71924100 @default.
- W4366352303 hasConcept C90924648 @default.
- W4366352303 hasConceptScore W4366352303C112705442 @default.
- W4366352303 hasConceptScore W4366352303C121608353 @default.
- W4366352303 hasConceptScore W4366352303C126322002 @default.
- W4366352303 hasConceptScore W4366352303C143998085 @default.
- W4366352303 hasConceptScore W4366352303C197934379 @default.
- W4366352303 hasConceptScore W4366352303C2778820342 @default.
- W4366352303 hasConceptScore W4366352303C71924100 @default.
- W4366352303 hasConceptScore W4366352303C90924648 @default.
- W4366352303 hasIssue "3" @default.
- W4366352303 hasLocation W43663523031 @default.
- W4366352303 hasLocation W43663523032 @default.
- W4366352303 hasOpenAccess W4366352303 @default.
- W4366352303 hasPrimaryLocation W43663523031 @default.
- W4366352303 hasRelatedWork W1993351621 @default.
- W4366352303 hasRelatedWork W2051764329 @default.
- W4366352303 hasRelatedWork W2074207917 @default.
- W4366352303 hasRelatedWork W2087813266 @default.
- W4366352303 hasRelatedWork W2362417726 @default.
- W4366352303 hasRelatedWork W2550800421 @default.
- W4366352303 hasRelatedWork W2806504080 @default.
- W4366352303 hasRelatedWork W3003574523 @default.
- W4366352303 hasRelatedWork W3184495456 @default.
- W4366352303 hasRelatedWork W4366822339 @default.
- W4366352303 hasVolume "41" @default.
- W4366352303 isParatext "false" @default.
- W4366352303 isRetracted "false" @default.
- W4366352303 workType "article" @default.